This study is testing a new approach for children with neuroblastoma that has come back or is hard to treat. It uses special immune cells called GINAKIT cells, which are made from your own blood. These cells are designed to recognize and kill cancer cells. The study will look at different doses of GINAKIT cells, both alone and in combination with another medicine called Etanercept. The main goal is to find the highest safe dose of GINAKIT cells when given with Etanercept. You may be able to join if you are between 1 and 21 years old and have neuroblastoma that meets certain criteria.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 70 participants to test different dose levels of GINAKIT cells, alone or with Etanercept.

What's involved

First, blood will be collected to create the GINAKIT cells. Before receiving GINAKIT cells, you will get chemotherapy (cyclophosphamide and fludarabine) for 3 days, followed by weekly Etanercept injections under the skin for 5 doses. You will then receive GINAKIT cells through an IV.

Compensation

Not stated in the trial record.

Follow-up

The main safety outcome will be measured 28 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.